Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Down 19.9% in February

Barinthus Biotherapeutics plc (NASDAQ:BRNS) saw a large drop in short interest in February. As of February 28th, there was short interest totalling 11,300 shares, a drop of 19.9% from the February 13th total of 14,100 shares. Based on an average trading volume of 38,300 shares, the short-interest ratio is presently 0.3 days. Currently, 0.0% of the company’s stock are sold short.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock opened at $1.06 on Monday. The firm’s 50-day moving average is $1.02 and its 200-day moving average is $1.13. Barinthus Biotherapeutics has a 1 year low of $0.80 and a 1 year high of $4.16. The company has a market cap of $42.64 million, a P/E ratio of -0.71 and a beta of -0.80.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their price objective on shares of Barinthus Biotherapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Monday, January 13th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new position in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics comprises about 0.0% of Gilead Sciences Inc.’s holdings, making the stock its 14th biggest position. Gilead Sciences Inc. owned approximately 1.54% of Barinthus Biotherapeutics as of its most recent filing with the Securities and Exchange Commission. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.